UCB Launches Neupro® in the U.S. to Treat Parkinson’s Disease and Restless Legs Syndrome

BRUSSELS & ATLANTA--(BUSINESS WIRE)--

UCB announced today that Neupro (Rotigotine Transdermal System) is now available in U.S. pharmacies. Neupro was approved by the U.S. Food and Drug Administration in April to treat the signs and symptoms of early and advanced stage idiopathic Parkinsons disease and moderate-to-severe primary Restless Legs Syndrome.

Neupro improves motor function and activities of daily living in patients with PD and provides effective symptom relief for patients with Restless Legs Syndrome (RLS). Neupro is a once-daily patch that provides continuous delivery of the dopamine agonist rotigotine for 24 hours.

Over 100,000 patients have been treated with Neupro worldwide, and seven clinical trials for the approved indications have demonstrated efficacy, safety and tolerability.

The availability of Neupro is an important step forward for U.S. patients living with Parkinsons disease and Restless Legs Syndrome, said Roch Doliveux, Chief Executive Officer, UCB. "UCB is dedicated to delivering innovative medicines like the Neupro transdermal patch to people living with serious illnesses such as Parkinsons disease and Restless Legs Syndrome, by combining the latest science and technology with our researchers' insights on the holistic needs of patients.

One million Americans are currently living with PD. The cardinal motor symptoms of PD include stiffness, tremors, slow movements and postural instability. These symptoms can have a broad impact on patients lives.

Restless Legs Syndrome may affect up to 23 million Americans. Patients with RLS often experience uncomfortable sensations in the legs, feet, arms, torso or head that typically occur during periods of rest and inactivity. Symptoms occur predominantly at night, but may emerge at any point in the day or night. Unmanaged moderate-to-severe RLS, in which patients experience symptoms two or more times a week, can be particularly disruptive for patients.

Parkinsons disease and Restless Legs Syndrome are serious, neurological diseases, said Dr. Joseph Jankovic, Professor of Neurology and Director, Parkinsons Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas. The often unpredictable, debilitating nature of these diseases can require consistent, sustained symptom control throughout the day and night.

Data Demonstrated Significant Symptom Improvement for Parkinsons Disease and Restless Legs Syndrome

The effectiveness of rotigotine in the treatment of the signs and symptoms of idiopathic PD was established in five parallel group, randomized, double-blind placebo-controlled trials conducted in the U.S. and abroad. Depending on trial design, PD patients underwent a weekly titration of rotigotine in 2 mg/24 hours increments to either the randomized dose or optimal dose.

Go here to read the rest:
UCB Launches Neupro® in the U.S. to Treat Parkinson’s Disease and Restless Legs Syndrome